Evolus Inc
NASDAQ:EOLS
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.47
17.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Evolus Inc
Evolus Inc
Other Current Liabilities
Evolus Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evolus Inc
NASDAQ:EOLS
|
Other Current Liabilities
$23.7m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$4.8B
|
CAGR 3-Years
31%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$24.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7.2B
|
CAGR 3-Years
40%
|
CAGR 5-Years
24%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$5.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
5%
|
|
Evolus Inc
Glance View
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.
See Also
What is Evolus Inc's Other Current Liabilities?
Other Current Liabilities
23.7m
USD
Based on the financial report for Sep 30, 2024, Evolus Inc's Other Current Liabilities amounts to 23.7m USD.
What is Evolus Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
33%
Over the last year, the Other Current Liabilities growth was 35%. The average annual Other Current Liabilities growth rates for Evolus Inc have been 33% over the past three years .
You don't have any saved screeners yet
